The company's discovery services support a wide range of global innovator companies from start-ups to large pharma companies, across a diverse set of therapeutic areas including oncology, CNS, antivirals, and inflammation among others
The company expects a potential sales turnover of Rs.350-500 crores at 100 % capacity utilization
It strengthens its presence to over 250 stores
Results from year two of the pivotal Phase 3 KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one
Seen in 1 in 3 million births, the malformation was detected at the antenatal stage during the mother's pregnancy
India’s dependency on China for pharma intermediates can change if there is a proper coordination between educational institutes, research institutes and pharma manufacturers
The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
InferVision's AI applications have been developed to quickly and accurately analyse signs of pulmonary infections from regular chest CT images. These images are processed to indicate ground-glass opacity and high tissue density, which are key findings of viral pneumonia caused by the coronavirus
The approval allows it to market its products in the country
Serum buys 50 per cent stake in Indian joint venture of SCHOTT Kaisha
Subscribe To Our Newsletter & Stay Updated
